Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31103869 | 0.85 | RXRA (0.35) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31104342 | 0.85 | ALDH1A1 (0.38) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31104454 | 0.83 | ALDH1A1 (0.36) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31104066 | 0.83 | RXRA (0.34) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31103876 | 0.83 | ALDH1A1 (0.38) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31104315 | 0.80 | PSMD10 (0.35) | ALDH1A1LMNAPOLBCYP4F2CYP4A11 | |
| SCHEMBL31104017 | 0.79 | ALDH1A1 (0.40) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31103882 | 0.77 | RXRA (0.42) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL31104171 | 0.71 | ALDH1A1 (0.40) | RXRARXRBRXRGALDH1A1LMNA | |
| SCHEMBL25341195 | 0.69 | RXRA (0.42) | RXRARXRBRXRGALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | VIVIDION THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2024182693-A1 | 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | VIVIDION THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | STAT3, JAK2, STAT1 | RXRA 839/4885RXRB 718/4885RXRG 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.